X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19185) 19185
Publication (1893) 1893
Book / eBook (242) 242
Book Review (206) 206
Magazine Article (40) 40
Book Chapter (33) 33
Dissertation (27) 27
Newspaper Article (21) 21
Conference Proceeding (15) 15
Newsletter (13) 13
Reference (3) 3
Paper (2) 2
Trade Publication Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17662) 17662
male (15652) 15652
female (13549) 13549
index medicus (10675) 10675
oncology (9670) 9670
middle aged (8847) 8847
aged (7657) 7657
breast-cancer (7599) 7599
adult (6600) 6600
cancer (6250) 6250
breast cancer (4727) 4727
animals (4406) 4406
chemotherapy (4138) 4138
breast neoplasms - drug therapy (4066) 4066
cell line, tumor (3069) 3069
research (2976) 2976
mice (2916) 2916
aged, 80 and over (2817) 2817
tumors (2813) 2813
metastasis (2786) 2786
care and treatment (2776) 2776
prognosis (2537) 2537
neoplasms - drug therapy (2470) 2470
treatment outcome (2354) 2354
expression (2260) 2260
antineoplastic agents - therapeutic use (2142) 2142
apoptosis (2070) 2070
antineoplastic combined chemotherapy protocols - therapeutic use (2012) 2012
health aspects (2006) 2006
cancer therapies (1941) 1941
breast neoplasms - pathology (1924) 1924
prostate cancer (1838) 1838
research article (1838) 1838
prostatic neoplasms - drug therapy (1816) 1816
medicine (1799) 1799
therapy (1799) 1799
gene expression (1754) 1754
analysis (1703) 1703
risk factors (1674) 1674
survival (1624) 1624
lung neoplasms - drug therapy (1522) 1522
proteins (1484) 1484
pharmacology & pharmacy (1451) 1451
genetic aspects (1433) 1433
patients (1421) 1421
carcinoma (1417) 1417
prostatic neoplasms - pathology (1369) 1369
neoplasm staging (1299) 1299
article (1298) 1298
antineoplastic agents - pharmacology (1292) 1292
multidisciplinary sciences (1281) 1281
studies (1272) 1272
breast (1271) 1271
medical prognosis (1263) 1263
retrospective studies (1229) 1229
mice, nude (1214) 1214
immunohistochemistry (1200) 1200
development and progression (1197) 1197
cell biology (1179) 1179
drug therapy (1143) 1143
gene expression regulation, neoplastic (1129) 1129
surgery (1129) 1129
science (1123) 1123
lung cancer (1118) 1118
colorectal cancer (1106) 1106
adolescent (1097) 1097
neoplasm metastasis (1083) 1083
dose-response relationship, drug (1078) 1078
kinases (1077) 1077
growth (1040) 1040
medicine & public health (1035) 1035
prostate-cancer (1035) 1035
cell proliferation - drug effects (1034) 1034
antineoplastic agents - adverse effects (1007) 1007
apoptosis - drug effects (992) 992
diagnosis (989) 989
medical research (987) 987
breast neoplasms - metabolism (980) 980
survival analysis (959) 959
cells (945) 945
disease-free survival (945) 945
signal transduction (939) 939
xenograft model antitumor assays (934) 934
antineoplastic combined chemotherapy protocols - adverse effects (932) 932
metastases (922) 922
young adult (917) 917
time factors (912) 912
biochemistry & molecular biology (902) 902
colorectal-cancer (902) 902
cell proliferation (884) 884
medicine, research & experimental (877) 877
survival rate (871) 871
angiogenesis (870) 870
follow-up studies (864) 864
mutation (851) 851
neoplasms. tumors. oncology. including cancer and carcinogens (848) 848
lung neoplasms - pathology (845) 845
antineoplastic agents - administration & dosage (835) 835
cell cycle (835) 835
risk (832) 832
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (196) 196
Collection Dvlpm't (Acquisitions) - Closed Orders (20) 20
Collection Dvlpm't (Acquisitions) - Vendor file (12) 12
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (8) 8
New College (Ivey) - Stacks (6) 6
Mt Sinai Hospital - Pathology (4) 4
OISE - Stacks (4) 4
UofT at Scarborough - Stacks (3) 3
Credit Valley Hospital - Stacks (2) 2
Humber River Regional Hospital - Finch Stacks (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Markham Stouffville Hospital - Stacks (2) 2
Robarts - Stacks (2) 2
Scarborough Hospital - General (2) 2
UTL at Downsview - May be requested (2) 2
Credit Valley Hospital - Reference (1) 1
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Not Returned (1) 1
Gerstein Science - Reference (1) 1
Providence Healthcare - Reference (1) 1
Scarborough Hospital - Birchmount (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's Hospital - Stacks (1) 1
Thomas Fisher Rare Book - May be requested at Fisher (1) 1
Trinity College (John W Graham) - Storage (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18575) 18575
Japanese (214) 214
German (201) 201
French (157) 157
Chinese (93) 93
Russian (64) 64
Italian (55) 55
Spanish (49) 49
Danish (39) 39
Polish (30) 30
Hungarian (17) 17
Dutch (13) 13
Portuguese (9) 9
Swedish (9) 9
Hebrew (7) 7
Norwegian (7) 7
Czech (5) 5
Finnish (5) 5
Korean (2) 2
Romanian (2) 2
Serbian (2) 2
Croatian (1) 1
Lithuanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Pathology, ISSN 0022-3417, 02/2013, Volume 229, Issue 3, pp. 422 - 429
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2141 - 2148
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2017, Volume 23, Issue 11, pp. 2730 - 2741
PURPOSE: to provide proof of principle of safety, breast tumor-specific uptake and positive tumor margin assessment of the systemically administered... 
ANTIBODIES | INDOCYANINE GREEN | IN-111-BEVACIZUMAB | ANGIOGENESIS | ONCOLOGY | SAFETY | CONSERVING SURGERY | MARGINS | OVARIAN-CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Optical Imaging | Bevacizumab - adverse effects | Humans | Male | Positron-Emission Tomography | Benzenesulfonates - administration & dosage | Vascular Endothelial Growth Factor A - genetics | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Feasibility Studies | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms, Male - diagnostic imaging | Female | Breast Neoplasms - diagnostic imaging | Antibodies, Monoclonal, Humanized - adverse effects | Breast Neoplasms, Male - diagnosis | Tissue Distribution - drug effects | Bevacizumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Breast Neoplasms - drug therapy | Indoles - adverse effects | Breast Neoplasms - pathology | Cell Line, Tumor | Breast Neoplasms - diagnosis | Breast Neoplasms, Male - pathology | Multiplexing | Drug delivery systems | Intravenous administration | Invasiveness | Feasibility studies | Fluorescence | I.R. radiation | Breast cancer | Patients | Bevacizumab | Surgical instruments | Histopathology | Microscopy | Experimental design | Safety engineering | Surgery | Breast | In vivo methods and tests | Safety | Vascular endothelial growth factor | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 743 - 754
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2017, Volume 23, Issue 2, pp. 407 - 415
Purpose: F-18-fluoroestradiol (FES) PET scans measure regional estrogen binding, and F-18-fluorodeoxyglucose (FDG) PET measures tumor glycolytic activity. We... 
POSITRON-EMISSION-TOMOGRAPHY | PROGNOSTIC-FACTORS | ONCOLOGY | F-18-FLUOROESTRADIOL | TUMORS | ESR1 | LESIONS | Breast Neoplasms, Male - genetics | Estradiol - analogs & derivatives | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Male | Positron-Emission Tomography | Fulvestrant | Neoplasm Metastasis | Adult | Breast Neoplasms, Male - diagnostic imaging | Female | Breast Neoplasms - diagnostic imaging | Fluorodeoxyglucose F18 - therapeutic use | Aromatase Inhibitors - administration & dosage | Antineoplastic Agents, Hormonal - administration & dosage | Estradiol - administration & dosage | Breast Neoplasms, Male - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Estrogen Receptor alpha - genetics | Breast Neoplasms - pathology | Aged | Breast Neoplasms, Male - pathology | Radiopharmaceuticals - therapeutic use | Estrogens | Estrogen | Estrogen receptors | Cytotoxicity | Cancer therapies | Metastases | Confidence intervals | Aromatase | Tomography | Bioindicators | Binding | Positron emission | Endocrine therapy | Breast cancer | Survival | Patients | ErbB-2 protein | Chemotherapy | Inhibitors | Experimental design | Glycolysis | Biomarkers | Breast | Positron emission tomography | Tumors | Cancer | FES PET | estrogen receptor | FDG PET | endocrine therapy
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer... 
Hematology, Oncology and Palliative Medicine | RECEPTOR | ONCOLOGY | PERTUZUMAB | DOCETAXEL | GUIDELINES | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 14, pp. 3529 - 3536
Purpose: ONT-380 (ARRY-380) is a potent and selective oral HER2 inhibitor. This Phase I study determined the MTD, pharmacokinetics (PK) and antitumor activity... 
LAPATINIB | CAPECITABINE | GROWTH-FACTOR RECEPTOR | THERAPY | TRASTUZUMAB | EFFICACY | ONCOLOGY | BRAIN METASTASES | NERATINIB | COMBINATION | Protein Kinase Inhibitors - pharmacokinetics | Breast Neoplasms, Male - genetics | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Male | Breast Neoplasms, Male - drug therapy | Protein Kinase Inhibitors - adverse effects | Breast Neoplasms - drug therapy | Drug-Related Side Effects and Adverse Reactions - pathology | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Neoplasm Metastasis | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Female | Aged | Receptor, ErbB-2 - antagonists & inhibitors | Breast Neoplasms, Male - pathology | Drug-Related Side Effects and Adverse Reactions - classification | Toxicity | Exanthema | Metastases | Anticancer properties | Pain | Vomiting | Quality | Hypokalemia | Constipation | Expansion | Epidermal growth factor receptors | Anemia | Diarrhea | Fatigue | Radioactive half-life | Nausea | Breast cancer | Pharmacology | Patients | ErbB-2 protein | Cough | Inhibitors | Experimental design | Design modifications | Transaminases | Antitumor activity | Solid tumors | Pharmacokinetics | Tumors | Cancer | Index Medicus
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 32, pp. 3626 - 3634
Purpose Neratinib is a potent irreversible pan-tyrosine kinase inhibitor with antitumor activity and acceptable tolerability in patients with human epidermal... 
ADJUVANT CHEMOTHERAPY | HKI-272 | TRIAL | THERAPY | SOLID TUMORS | TRASTUZUMAB | ONCOLOGY | TYROSINE KINASE INHIBITOR | PHASE-II | EXPANDED ACCESS | LAPATINIB PLUS CAPECITABINE | Capecitabine | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Diarrhea - chemically induced | Quinolines - administration & dosage | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Paresthesia - chemically induced | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Administration, Oral | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Breast Neoplasms, Male - drug therapy | Breast Neoplasms - drug therapy | Syndrome | Breast Neoplasms, Male - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Deoxycytidine - analogs & derivatives | Quinolines - adverse effects | Trastuzumab | Index Medicus
Journal Article
The Oncologist, ISSN 1083-7159, 06/2015, Volume 20, Issue 6, pp. 586 - 592
Journal Article